We are live on ! Find out more
FLSM

Frazier Life Sciences Management Portfolio holdings

AUM $4.59B
1-Year Est. Return 237.58%
This Fund
S&P 500
This Quarter Est. Return
+30.23%
1 Year Est. Return
+237.58%
3 Year Est. Return
+865.83%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$1.87B
AUM Growth
+$365M
Cap. Flow
+$52.7M
Cap. Flow %
2.82%
Top 10 Hldgs %
59.4%
Holding
57
New
5
Increased
14
Reduced
4
Closed
8

Top Buys

Rank Stock Value
1
ETNB
89bio
ETNB
+$18.4M
2
GPCR icon
Structure Therapeutics
GPCR
+$18.2M
3
APLS
Apellis Pharmaceuticals
APLS
+$13.8M
4
EWTX icon
Edgewise Therapeutics
EWTX
+$12.8M
5
MDGL icon
Madrigal Pharmaceuticals
MDGL
+$12.1M

Top Sells

Rank Stock Value
1
CRNX
Crinetics Pharmaceuticals
CRNX
+$36.6M
2
ELVN icon
Enliven Therapeutics
ELVN
+$14.3M
3
SNDX icon
Syndax Pharmaceuticals
SNDX
+$8.71M
4
REPL icon
Replimune Group
REPL
+$6.62M
5
PRTA icon
Prothena Corp
PRTA
+$6.17M

Sector Composition

Rank Sector Weight
1 Healthcare 99.92%
2 Miscellaneous 0.08%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MIRM icon
1
Mirum Pharmaceuticals
MIRM
$6.11B
$192M 10.25%
6,495,392
+25,000
+0.4% +$757K
HLVX
2
DELISTED
HilleVax
HLVX
$157M 8.39%
9,781,472
– –
NAMS icon
3
NewAmsterdam Pharma
NAMS
$3.01B
$136M 7.25%
12,131,705
– –
KRYS icon
4
Krystal Biotech
KRYS
$10.4B
$123M 6.56%
988,460
– –
BBIO icon
5
BridgeBio Pharma
BBIO
$14.8B
$110M 5.88%
2,725,949
– –
RYTM icon
6
Rhythm Pharmaceuticals
RYTM
$7.09B
$109M 5.83%
2,371,304
– –
PHAT icon
7
Phathom Pharmaceuticals
PHAT
$759M
$92.3M 4.93%
10,109,279
– –
PCVX icon
8
Vaxcyte
PCVX
$9.05B
$73.1M 3.91%
1,164,405
– –
VRNA
9
DELISTED
Verona Pharma
VRNA
$59.9M 3.2%
3,014,349
– –
ALPN
10
DELISTED
Alpine Immune Sciences Inc
ALPN
$59.7M 3.19%
3,131,008
+145,251
+5% +$2.02M
APLS
11
DELISTED
Apellis Pharmaceuticals
APLS
$53M 2.83%
885,165
+271,122
+44% +$13.8M
RCKT icon
12
Rocket Pharmaceuticals
RCKT
$412M
$45.6M 2.44%
1,523,013
+120,000
+9% +$2.65M
IRON icon
13
Disc Medicine
IRON
$3.02B
$45.3M 2.42%
785,000
+130,000
+20% +$6.66M
KALV
14
DELISTED
KalVista Pharmaceuticals
KALV
$44.4M 2.37%
3,622,294
+383,435
+12% +$3.49M
TARS icon
15
Tarsus Pharmaceuticals
TARS
$3.93B
$36.2M 1.94%
1,787,527
– –
EWTX icon
16
Edgewise Therapeutics
EWTX
$4.84B
$29.2M 1.56%
2,667,203
+1,818,181
+214% +$12.8M
RVMD icon
17
Revolution Medicines
RVMD
$45.1B
$28.6M 1.53%
997,455
– –
ANTX icon
18
AN2 Therapeutics
ANTX
$217M
$28.5M 1.52%
1,388,889
– –
ARQT icon
19
Arcutis Biotherapeutics
ARQT
$3.05B
$28.3M 1.51%
8,764,232
+80,000
+0.9% +$217K
JBIO
20
Jade Biosciences
JBIO
$1.26B
$27.3M 1.46%
34,425
– –
AUTL
21
Autolus Therapeutics
AUTL
$580M
$24.1M 1.29%
3,746,857
– –
MGNX icon
22
MacroGenics
MGNX
$274M
$23.1M 1.24%
2,401,704
+598,500
+33% +$4.14M
ACAD icon
23
Acadia Pharmaceuticals
ACAD
$4.81B
$22.9M 1.22%
730,917
+100,020
+16% +$2.39M
ETNB
24
DELISTED
89bio
ETNB
$22.3M 1.19%
+2,000,000
New +$18.4M
MRUS
25
DELISTED
Merus
MRUS
$20.5M 1.1%
746,479
– –
1
2 3

Similar funds

AF
Avanza Fonder Stockholm, Sweden $4.59B AUM 41.03% 1-Year Est. Return
BWA
Brave Warrior Advisors New York $4.59B AUM 9.32% 1-Year Est. Return
CCA
Conestoga Capital Advisors Wayne, Pennsylvania $4.6B AUM 16.08% 1-Year Est. Return
AT
Arbejdsmarkedets Tillaegspension Hilleroed $4.6B AUM
SLG
Silver Lake Group Menlo Park, California $4.58B AUM 24.86% 1-Year Est. Return
TYCC
Texas Yale Capital Corp St. Petersburg, Florida $4.61B AUM 50.58% 1-Year Est. Return
LP
Longaeva Partners Chicago, Illinois $4.58B AUM 43.91% 1-Year Est. Return
CSP
Cary Street Partners Richmond, Virginia $4.58B AUM 24% 1-Year Est. Return

Frazier Life Sciences Management's Q4 2023 Portfolio in Review

As of Q4 2023, Frazier Life Sciences Management held 57 positions worth $1.87B, up 24% from $1.51B the previous quarter. Its ten largest holdings account for 59% of the portfolio.

Frazier Life Sciences Management's Q4 2023 filing shows 5 new, 14 increased, 4 reduced and 8 closed positions. Its largest new stake was 89bio: 2,000,000 shares worth $22.3M. The largest sale was Crinetics Pharmaceuticals, an estimated $36.6M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier, followed by Miscellaneous.

  • Frazier Life Sciences Management's largest Q4 2023 buy was 89bio: 2,000,000 shares worth $22.3M.
  • Frazier Life Sciences Management added most to Apellis Pharmaceuticals in Q4 2023, an estimated $13.8M increase.
  • Frazier Life Sciences Management's biggest Q4 2023 reduction was Crinetics Pharmaceuticals, cutting an estimated $36.6M.
  • Frazier Life Sciences Management fully exited Enliven Therapeutics in Q4 2023, selling an estimated $14.3M.
  • Frazier Life Sciences Management's ten largest holdings make up 59% of its $1.87B portfolio in Q4 2023.
  • Frazier Life Sciences Management opened 5 new positions and closed 8 in Q4 2023.
  • Frazier Life Sciences Management's portfolio value rose 24% quarter-over-quarter to $1.87B.

Based on Frazier Life Sciences Management's 13F filing for Q4 2023, filed 14 Feb 2024.